

[Navigation überspringen](#)

[Combination Therapy](#) Uproleselan (GMI-1271), an E-Selectin Antagonist; Indoximod + Standard Induction Chemotherapy; CT & Venetoclax in Elderly AML (CAVEAT); Venetoclax & Hypomethylating Agents; Effective Immunomodulation with Pomalidomide; CPX-351;

[Targeted Therapy](#) Beat AML Umbrella Study; Gilteritinib, Ivosidenib or Enasidenib Combined with Induction & Consolidation CT; Ivosidenib; Durable Remissions and Transfusion Independence; Enasidenib + Venetoclax; Superior Anti-Leukemic Activity; Quizartinib

[New Treatment Strategies](#) XmAb14045 a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Flotetuzumab a CD123xCD3 Bispecific DART® Protein; Tagraxofusp (SL-401) in BPDCN; Alisertib, combined with Induction CT; Ven + MDM2 Inhibitor Idasanutlin; Mcl-1/CDK9 Targeting By AZD5991/AZD4573

[Immunotherapy](#) CLL1-CD33 CAR T Cell (CTC) Therapy; NKG2D CTC Therapy; FLT3 Inhibition Increases FLT3 Expression That Exposes FLT3-ITD+ AML Blasts to Elimination By FLT3 CTC; Oncogenic-Drivers Dictate Immune Responses; I. A & Nivo in AML&MDS; AZA+Nivo & AZA+Nivo+Ipi